Fairmount Funds Management Llc - Net Worth and Insider Trading

Fairmount Funds Management Llc Net Worth

The estimated net worth of Fairmount Funds Management Llc is at least $96 Million dollars as of 2024-11-05. Fairmount Funds Management Llc is the Director, 10% Owner of Dianthus Therapeutics Inc and owns about 1,903,833 shares of Dianthus Therapeutics Inc (DNTH) stock worth over $54 Million. Fairmount Funds Management Llc is also the See Remarks of Cogent Biosciences Inc and owns about 3,558,975 shares of Cogent Biosciences Inc (COGT) stock worth over $42 Million. Details can be seen in Fairmount Funds Management Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Fairmount Funds Management Llc has not made any transactions after 2023-09-26 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Fairmount Funds Management Llc

To

Fairmount Funds Management Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Fairmount Funds Management Llc owns 5 companies in total, including Cogent Biosciences Inc (COGT) , Viridian Therapeutics Inc (VRDN) , and Spyre Therapeutics Inc (SYRE) among others .

Click here to see the complete history of Fairmount Funds Management Llc’s form 4 insider trades.

Insider Ownership Summary of Fairmount Funds Management Llc

Ticker Comapny Transaction Date Type of Owner
COGT Cogent Biosciences Inc 2023-06-09 10 percent owner & other: See Remarks
VRDN Viridian Therapeutics Inc 2020-10-27 director & other: See Remarks
SYRE Spyre Therapeutics Inc 2023-06-22 director & 10 percent owner
LIMIT LIMIT 2023-07-13 director
LIMIT LIMIT 2023-09-19 director & 10 percent owner

Fairmount Funds Management Llc Latest Holdings Summary

Fairmount Funds Management Llc currently owns a total of 2 stocks. Among these stocks, Fairmount Funds Management Llc owns 1,903,833 shares of Dianthus Therapeutics Inc (DNTH) as of September 26, 2023, with a value of $54 Million and a weighting of 56.03%. Fairmount Funds Management Llc also owns 3,558,975 shares of Cogent Biosciences Inc (COGT) as of June 9, 2023, with a value of $42 Million and a weighting of 43.97%.

Latest Holdings of Fairmount Funds Management Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DNTH Dianthus Therapeutics Inc 2023-09-26 1,903,833 28.28 53,840,397
COGT Cogent Biosciences Inc 2023-06-09 3,558,975 11.87 42,245,033

Holding Weightings of Fairmount Funds Management Llc


Fairmount Funds Management Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Fairmount Funds Management Llc has made a total of 3 transactions in Dianthus Therapeutics Inc (DNTH) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Dianthus Therapeutics Inc is the acquisition of 30,000 shares on September 26, 2023, which cost Fairmount Funds Management Llc around $394,500.

According to the SEC Form 4 filings, Fairmount Funds Management Llc has made a total of 2 transactions in Cogent Biosciences Inc (COGT) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Cogent Biosciences Inc is the acquisition of 800,000 shares on June 9, 2023, which cost Fairmount Funds Management Llc around $10 Million.

Insider Trading History of Fairmount Funds Management Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Fairmount Funds Management Llc Trading Performance

GuruFocus tracks the stock performance after each of Fairmount Funds Management Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Fairmount Funds Management Llc is 1.47%. GuruFocus also compares Fairmount Funds Management Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Fairmount Funds Management Llc within 3 months outperforms 1 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Fairmount Funds Management Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Fairmount Funds Management Llc

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
4 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 4.55 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 5.03 LIMIT LIMIT LIMIT LIMIT LIMIT

Fairmount Funds Management Llc Ownership Network

Ownership Network List of Fairmount Funds Management Llc

No Data

Ownership Network Relation of Fairmount Funds Management Llc

Insider Network Chart

Fairmount Funds Management Llc Owned Company Details

What does Cogent Biosciences Inc do?

Who are the key executives at Cogent Biosciences Inc?

Fairmount Funds Management Llc is the 10 percent owner & other: See Remarks of Cogent Biosciences Inc. Other key executives at Cogent Biosciences Inc include Chief Legal Officer Evan Kearns , Chief Financial Officer John L. Green , and Chief Scientific Officer John Edward Robinson .

Cogent Biosciences Inc (COGT) Insider Trades Summary

Over the past 18 months, Fairmount Funds Management Llc made 1 insider transaction in Cogent Biosciences Inc (COGT) with a net purchase of 800,000.

In summary, during the past 3 months, insiders sold 0 shares of Cogent Biosciences Inc (COGT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cogent Biosciences Inc (COGT) were sold and 800,000 shares were bought by its insiders, resulting in a net purchase of 800,000 shares.

Cogent Biosciences Inc (COGT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cogent Biosciences Inc Insider Transactions

No Available Data

Fairmount Funds Management Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Fairmount Funds Management Llc. You might contact Fairmount Funds Management Llc via mailing address: 200 Barr Harbor Drive, Suite 400, West Conshohocken Pa 19428.